

Contents

Imatinib Mesylate	1
Cornelius F. Waller	
1 Introduction.	2
2 Structure and Mechanisms of Action	4
3 Preclinical Data	5
4 Clinical Data in CML.	7
4.1 Phase I Trials.	7
4.2 Phase II Studies	8
4.3 Phase III Study (IRIS Trial).	9
5 Treatment Recommendations for the Use of Imatinib in Chronic Phase CML.	10
6 Imatinib in Combination with Other Drugs	12
7 Imatinib: Other Targets	13
8 Side Effects/Toxicity	14
9 Clinical Pharmacology and Drug Interactions	17
10 Biomarkers	18
10.1 CML.	18
10.2 GIST.	18
11 Summary and Perspectives	19
References	20
 Dasatinib	 27
Markus Lindauer and Andreas Hochhaus	
1 Introduction.	28
2 Structure and Mechanism of Action	29
3 Preclinical Data	31
3.1 Inhibition of ABL.	31
3.2 Inhibition of SRC.	32
3.3 Inhibition of KIT	33
3.4 Inhibition of Platelet-Derived Growth Factor Receptor (PDGFR) α and β Tyrosine Kinases	33
3.5 Inhibition of Ephrin Receptor Tyrosine Kinases.	34
3.6 Inhibition of TEC Family Kinases and BTK	34

4	Clinical Data	35
4.1	Pharmacokinetic Profile	35
4.2	Clinical Trials with Dasatinib	35
4.3	Clinical Trials with Dasatinib in CML Patients: Overview . . .	35
4.4	Dasatinib in Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)	42
4.5	Dasatinib in Philadelphia-Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis	43
4.6	Dasatinib in the Treatment of Solid Tumors	45
5	Toxicity	48
6	Drug Interactions	53
7	Biomarkers	54
8	Summary and Perspectives	55
	References	56

Nilotinib 67

Benjamin N. Ostendorf, Philipp le Coutre, Theo D. Kim
and Alfonso Quintás-Cardama

1	Introduction.	68
2	Structure and Mechanism of Action	69
3	Preclinical Data	69
4	Clinical Data	70
4.1	Nilotinib Phase I Trial	70
4.2	Nilotinib Second- and Third-Line Therapy	71
4.3	Nilotinib First-Line Therapy	72
4.4	Resistance to Nilotinib	73
5	Toxicity	74
6	Drug Interactions	76
7	Biomarkers	77
8	Summary and Perspectives	77
	References	78

Bosutinib: A Novel Second-Generation Tyrosine Kinase Inhibitor 81

Susanne Isfort, Gunhild Keller-v. Amsberg, Philippe Schafhausen,
Steffen Koschmieder and Tim H. Brümmendorf

1	Structure and Mechanism of Action	82
1.1	Chemical Structure	82
1.2	Mechanism of Action (Target Profile).	82
1.3	SRC Kinase Inhibition	83
1.4	ABL and BCR-ABL Inhibition	83

2	Preclinical Data	84
2.1	BCR-ABL-Dependent Diseases	84
2.2	Potential New Hematologic Diseases/Targets	86
2.3	Breast Cancer	86
2.4	Colorectal Cancer	87
2.5	Non-small Cell Lung Cell Cancer	87
2.6	Polycystic Kidney Disease	87
3	Clinical Data	88
3.1	Bosutinib in Treatment-Resistant/-Intolerant CML	88
3.2	Bosutinib in CML First-Line Treatment	91
3.3	Bosutinib in Solid Tumors	92
4	Toxicity	92
5	Drug Interactions	93
6	Biomarkers	93
7	Summary and Perspectives	94
	References	95

Ponatinib: A Third-Generation Inhibitor for the Treatment of CML 99

Julius Wehrle, Heike L. Pahl and Nikolas von Bubnoff

1	Resistance to Treatment in CML	100
2	Second-Generation Inhibitors	101
3	Ponatinib: A New Third-Generation Inhibitor	101
	References	105

Erlotinib 109

M. Steins, M. Thomas and M. Geißler

1	Introduction	110
2	Mechanism of Action	110
3	Non-Small Cell Lung Cancer	112
4	Pancreatic Adenocarcinoma	115
5	Hepatocellular Carcinoma	118
6	Other Tumour Entities	120
	References	120

Lapatinib 125

Minna Nolting, Tanja Schneider-Merck and Martin Trepel

1	Introduction	126
1.1	The Epidermal Growth Factor Receptor Family of Tyrosine Kinases	126
1.2	Human Epidermal Growth Factor Receptors and Their Inhibition in Cancer	127
2	Structure and Mechanism of Action	128
3	Pharmacology	130

4	Results from Clinical Trials	130
4.1	Efficacy in Breast Cancer	130
4.2	Efficacy in Gastroesophageal Cancer	137
4.3	Tolerability	138
5	Conclusion and Future Perspectives	139
	References	140

Sorafenib: Targeting Multiple Tyrosine Kinases in Cancer 145

Jens Hasskarl

1	Introduction.	146
2	Structure and Mechanism of Action	147
3	Clinical Data	149
3.1	Phase I	149
3.2	Experience in Special Patient Populations	149
3.3	Experience in Pediatric Patients	150
3.4	Active Clinical Trials	151
3.5	Sorafenib in the Treatment of Renal Cell Cancer	151
3.6	Sorafenib in the Treatment of Hepatocellular Cancer	153
3.7	Sorafenib in the Treatment of Lung Cancer	153
3.8	Sorafenib in the Treatment of Breast Cancer	154
3.9	Sorafenib in the Treatment of Malignant Melanoma	154
3.10	Sorafenib in the Treatment of Prostate Cancer	154
3.11	Sorafenib in the Treatment of Head and Neck Cancer	155
3.12	Sorafenib in the Treatment of Ovarian Cancer	155
3.13	Sorafenib in the Treatment of Brain Tumors	155
3.14	Sorafenib in the Treatment of Thyroid Cancer	155
3.15	Sorafenib in the Treatment of Hematologic Diseases	156
4	Clinical Safety Profile of Sorafenib	157
5	Conclusion and Future Perspectives	157
	References	157

Sunitinib in the Treatment of Advanced Solid Tumors 165

Amal Imbulgoda, Daniel Y. C. Heng and Christian Kollmannsberger

1	Structure and Mechanism of Action	166
2	Preclinical Data	166
3	Clinical Data	167
3.1	Renal Cell Carcinoma	167
3.2	Gastrointestinal Stromal Tumors	170
3.3	Pancreatic Neuroendocrine Tumors	172
3.4	Other Solid Tumors	174
4	Toxicity	175
5	Drug Interactions	178
6	Biomarkers	178

7	Summary and Perspectives	179
	References	179
Regorafenib		185
Thomas J. Ettrich and Thomas Seufferlein		
1	Structure, Mechanism of Action, and Pharmacokinetics	186
1.1	Mechanism of Action	186
1.2	Pharmacokinetics and Elimination	186
1.3	Regorafenib in Renal or Hepatic Impairment	187
2	Preclinical Data	187
3	Clinical Data	188
3.1	Regorafenib in Metastatic Colorectal Cancer	188
3.2	Regorafenib in Metastatic Gastrointestinal Stromal Tumors	189
3.3	Regorafenib in Hepatocellular Carcinoma	191
3.4	Regorafenib in Metastatic Renal Cell Carcinoma	191
3.5	Regorafenib in Soft Tissue Sarcoma	192
4	Detailed Analysis of Toxicity	192
4.1	Dermatological Toxicity	192
4.2	Hypertension, Cardiac Ischemia, and Infarction	193
4.3	Hepatotoxicity	193
4.4	Gastrointestinal Perforation or Fistula	193
4.5	Hemorrhage	193
4.6	Embryo–Fetal Toxicity	194
5	Drug Interactions	194
5.1	Effect of Strong CYP3A4 Inducers	194
5.2	Effect of Strong CYP3A4 Inhibitors	194
5.3	Effect of Regorafenib on UGT1A1 Substrates	194
6	Biomarkers	194
7	Summary and Perspectives	195
	References	195
Crizotinib		197
David F. Heigener and Martin Reck		
1	Structure and Mechanism of Action	198
2	Preclinical Data	198
3	Clinical Data	199
3.1	NSCLC	199
3.2	Other Entities	202
4	Toxicity	202
5	Drug Interactions	202
6	Biomarkers	203
7	Summary and Perspectives	203
	References	204

Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor	207
Carsten Gröllich	
1 Introduction.	208
2 Preclinical Properties and Pharmacokinetics	209
3 Clinical Trials	210
3.1 Phase I	210
3.2 Phase III EXAM Trial.	210
3.3 Phase II Trial in Prostate Cancer	211
4 Discussion.	212
References	214
Vemurafenib	215
Claus Garbe, Sail Abusaif and Thomas K. Eigentler	
1 Introduction.	216
2 Structure and Mechanism of Action	217
3 Preclinical Data	218
4 Pharmacokinetics and Drug Interactions	218
5 Vemurafenib in Melanoma	219
6 Toxicity	220
7 Vemurafenib in Colorectal Cancer	221
8 Vemurafenib in Papillary Thyroid Cancer	221
9 Vemurafenib in Non-Small-Cell Lung Cancer	222
10 Vemurafenib in Hairy Cell Leukaemia	222
11 Biomarkers and Monitoring of Vemurafenib Treatment	222
12 Summary and Perspectives	223
References	223
Dabrafenib	227
Radhika Kainthla, Kevin B. Kim and Gerald S. Falchook	
1 Introduction.	228
2 Mechanism of Action	228
3 Preclinical Data	229
3.1 Dabrafenib Activity in V600 BRAF-Mutant Cell Lines.	229
3.2 Dabrafenib and Immune Modulation.	230
3.3 Mechanisms of Dabrafenib Resistance	230
4 Metastatic Melanoma	232
4.1 Monotherapy	232
4.2 Monotherapy in Brain Metastasis	233
4.3 Combination Therapy with Trametinib	234

5	Other Cancers With V600E BRAF Mutations	235
5.1	Dabrafenib Monotherapy	235
5.2	Combination Therapy with Trametinib in Colorectal Cancer (CRC).	235
6	Toxicity	236
7	Drug Interactions	236
8	Biomarkers	237
8.1	Predictors of Response	237
8.2	Pharmacodynamic Markers	237
9	Summary and Perspectives	237
	References	238
	Trametinib	241
	Robert Zeiser	
1	Structure and Mechanism of Action	242
2	Preclinical Data	242
3	Clinical Data	244
4	Toxicity	245
5	Drug Interactions	246
6	Biomarkers	246
7	Summary and Perspectives	247
	References	247
	Ruxolitinib	249
	Heiko Becker, Monika Engelhardt, Nikolas von Bubnoff and Ralph Wäsch	
1	Structure and Mechanism of Action	250
2	Preclinical Data	250
3	Clinical Data	251
4	Toxicity	254
5	Drug Interactions	255
6	Biomarkers	256
7	Summary and Perspectives	256
	References	256
	Ibrutinib	259
	Mark-Alexander Schwarzbich and Matthias Witzens-Harig	
1	Structure and Mechanism of Action	260
2	Preclinical Data	262
3	Clinical Data	263
4	Toxicity	264
5	Drug Interactions	265
6	Summary and Perspectives	265
	References	265

Decitabine	269
Björn Hackanson and Michael Daskalakis	
1 Introduction	270
2 Structure and Mechanism of Action	271
2.1 Single-Agent Decitabine in MDS and AML	271
2.2 Combination Treatment with Decitabine in MDS and AML	275
2.3 Decitabine as a Preparative Agent for Allogeneic Stem Cell Transplantation	278
2.4 Immunomodulation with Decitabine	279
2.5 Decitabine Treatment in Other Diseases	281
3 Toxicity	286
4 Drug Interactions	287
5 Biomarkers	287
6 Summary and Perspectives	287
References	288
5-Azacytidine/5-Azacitidine	299
Antonia M. S. Müller and Mareike Florek	
1 Introduction	300
2 Structure and Mechanism of Action	301
2.1 Structure	301
2.2 Mechanism of Action	301
2.3 Pharmacology, Bioavailability, Half-Life, Elimination, Drug–Drug Interactions	302
3 Toxicity	303
3.1 Safety, Side Effects, and Contraindications	303
4 Preclinical Data	305
5 Clinical Use of 5-Azacytidine	306
5.1 Early Studies	306
5.2 Randomized Phase III Studies of 5-Azacytidine	307
5.3 Current Questions and Preliminary Results	310
6 Conclusion and Perspective	317
References	318
Bortezomib	325
Hermann Einsele	
1 Mode of Action	326
2 Antitumor Effects	327
3 Clinical Application of Proteasome Inhibitors	329
4 Bortezomib	330
5 Bortezomib-Based Combination Therapy for Multiple Myeloma	332
6 Treatment Options for Patients Eligible for Transplant	333
7 Next-Generation Proteasome Inhibitors	335
References	337

Lenalidomide	347
Katja Weisel and Lothar Kanz	
1 Introduction.	348
2 Structure and Mechanism of Action	348
3 Clinical Data.	349
4 Lenalidomide in Multiple Myeloma	349
5 Lenalidomide in Relapsed Multiple Myeloma	350
6 Lenalidomide in Newly Diagnosed Multiple Myeloma	350
7 Maintenance Treatment with Lenalidomide in Multiple Myeloma After ASCT	351
8 Lenalidomide in MDS	352
9 Lenalidomide in Other Hematological Malignancies	353
10 Lenalidomide in Solid Tumors	354
11 Conclusions and Future Perspectives	355
References	355
 Pomalidomide	 359
Monika Engelhardt, Ralph Wäsch, Heike Reinhardt and Martina Kleber	
1 Structure and Mechanism of Action	360
2 Preclinical Data	361
3 Clinical Data	364
4 MM	364
5 AL Amyloidosis	367
6 Myelofibrosis	367
7 Toxicity	368
8 Drug Interactions	369
9 Biomarkers	369
10 Summary and Perspectives	370
References	370
 Everolimus	 373
Jens Hasskarl	
1 Introduction.	374
2 Structure and Mechanism of Action	376
3 Preclinical Data	376
4 Clinical Data	377
4.1 Pharmacokinetics and Pharmacodynamics	377
4.2 Clinical Development of Everolimus.	378
5 Toxicity	387
6 Drug Interactions	387
7 Biomarkers	387
8 Summary and Perspectives	388
References	388

Temsirolimus	393
Michael Schulze, Christian Stock, Massimo Zaccagnini, Dogu Teber and Jens J. Rassweiler	
1 Introduction.	394
2 Development.	395
3 Structure and Mechanism of Action.	395
4 Clinical Data.	397
5 Safety and Efficacy	397
6 Side Effects.	399
7 Conclusion and Future Perspectives	400
References.	401
 Vismodegib	 405
F. Meiss and R. Zeiser	
1 Introduction.	406
2 Structure and Mechanism of Action.	407
2.1 Structure	407
2.2 Mechanism of Action	407
3 Preclinical Data	408
4 Clinical Data.	408
4.1 Vismodegib in Basal Cell Carcinoma (BCC)	408
4.2 Vismodegib in Colorectal Cancer	410
4.3 Vismodegib in Ovarian Cancer	410
4.4 Vismodegib in Small Lung Cell Cancer	411
4.5 Vismodegib in Hematologic Diseases	411
4.6 Vismodegib in Medulloblastoma	412
5 Toxicity	412
6 Drug Interactions.	414
7 Summary and Perspectives	414
References.	415